Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Moriarty

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Malaria Journal|April 11, 2023
Correction: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in EthiopiaAshenaf Assefa, Hussein Mohammed, Anjoli Anand, et al.
Malaria Journal|December 1, 2022
Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in EthiopiaAshenafi Assefa, Hussein Mohammed, Anjoli Anand, et al.
European Cells & Materials|October 18, 2021
Bone infection: a clinical priority for clinicians, scientists and educatorsT F Moriarty, G Muthukrishnan, J L Daiss, et al.
Malaria Journal|December 25, 2021
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in UgandaChris Ebong, Asadu Sserwanga, Jane Frances Namuganga, et al.
Malaria Journal|February 8, 2022
Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in UgandaChris Ebong, Asadu Sserwanga, Jane Frances Namuganga, et al.
Malaria Journal|June 12, 2025
Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatmentVeronika R Laird, Mateusz M Plucinski, Meera Venkatesan, et al.
The American Journal of Tropical Medicine and Hygiene|September 7, 2021
Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial ResistanceLeah F Moriarty, Papy Mandoko Nkoli, Joris Losimba Likwela, et al.
The Lancet. Infectious Diseases|April 17, 2021
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy studyAline Uwimana, Noella Umulisa, Meera Venkatesan, et al.
Emerging Infectious Diseases|June 21, 2021
Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014-2018Sarah E Schmedes, Dhruviben Patel, Simran Dhal, et al.
PLOS Global Public Health|May 29, 2026
Target product profiles of laboratory and data analytical frameworks for genotyping to monitor antimalarial efficacyMateusz M Plucinski, Amy Wesolowski, Inna Gerlovina, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Malaria Journal|April 11, 2023
Correction: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in EthiopiaAshenaf Assefa, Hussein Mohammed, Anjoli Anand, et al.
Malaria Journal|December 1, 2022
Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in EthiopiaAshenafi Assefa, Hussein Mohammed, Anjoli Anand, et al.
European Cells & Materials|October 18, 2021
Bone infection: a clinical priority for clinicians, scientists and educatorsT F Moriarty, G Muthukrishnan, J L Daiss, et al.
Malaria Journal|December 25, 2021
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in UgandaChris Ebong, Asadu Sserwanga, Jane Frances Namuganga, et al.
Malaria Journal|February 8, 2022
Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in UgandaChris Ebong, Asadu Sserwanga, Jane Frances Namuganga, et al.
Malaria Journal|June 12, 2025
Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatmentVeronika R Laird, Mateusz M Plucinski, Meera Venkatesan, et al.
The American Journal of Tropical Medicine and Hygiene|September 7, 2021
Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial ResistanceLeah F Moriarty, Papy Mandoko Nkoli, Joris Losimba Likwela, et al.
The Lancet. Infectious Diseases|April 17, 2021
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy studyAline Uwimana, Noella Umulisa, Meera Venkatesan, et al.
Emerging Infectious Diseases|June 21, 2021
Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014-2018Sarah E Schmedes, Dhruviben Patel, Simran Dhal, et al.
PLOS Global Public Health|May 29, 2026
Target product profiles of laboratory and data analytical frameworks for genotyping to monitor antimalarial efficacyMateusz M Plucinski, Amy Wesolowski, Inna Gerlovina, et al.
Pageof 11